肝纤维化新型无创检测:超越简单检测在代谢功能障碍相关脂肪性肝病中的应用
本范围综述系统检索近5年(2020年至今)文献,评估代谢功能障碍相关脂肪性肝病(MASLD)中新型无创肝病评估(NILDA)的表现。912条记录中48项符合纳入标准,15种新评分中部分在验证研究中表现良好且包含常规可用元素。作者提出以FIB-4指数起始,FIB-4>1.3者使用Agile 3+或4识别进展期纤维化或肝硬化。
要点
- FIB-4指数因可得性高、成本低、阴性预测值高而作为起始检测。
- FIB-4>1.3者建议使用Agile 3+或4识别进展期纤维化或肝硬化。
- 部分新型评分有良好至优秀区分度,但成本和可得性可能限制实践应用。
核心结论
- NILDA是MASLD纤维化评估中肝活检的有效替代方法,并可能作为识别适合更新疗法的候选患者的工具。
研究设计与样本
- 范围综述,系统检索过去5年(2020年至今)评估MASLD中NILDA的研究。
- 912条记录中48项符合纳入标准:37项通过系统综述纳入,11项由作者识别。
- 评估了15种新型评分。
主要发现
- 15种新型评分中,部分在脂肪性肝病验证研究中表现良好,并包含常规可用的元素。
- 若干新型评分具有良好至优秀的区分度,但其成本和可得性可能限制实践中的应用。
关键数值与推荐
- FIB-4指数、天冬氨酸血小板比率指数以及瞬时弹性成像和磁共振弹性成像的肝脏硬度测量是指南支持的无创肝病评估工具,但受限于不确定范围和不同患者人群中诊断性能的差异。
- 作者提出从FIB-4指数开始,因其可得性、低成本和高阴性预测值。
- 作者提出对FIB-4>1.3者使用Agile 3+或4识别进展期纤维化或肝硬化。
临床怎么用
- 作者提出以FIB-4指数作为起始无创评估。
- 作者提出对FIB-4>1.3的患者使用Agile 3+或4识别进展期纤维化或肝硬化。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Noninvasive tests serve as alternative options to liver biopsy for the diagnosis of liver fibrosis. The Fibrosis 4 (FIB-4) index, aspartate platelet ratio index, and liver stiffness measurement by transient and magnetic resonance elastography are guideline-supported tools for noninvasive liver disease assessment but are limited by indeterminate ranges and varying diagnostic performance among different patient populations. In this scoping review, we evaluate the performance of novel noninvasive liver disease assessments in metabolic dysfunction-associated steatotic liver disease (MASLD) not discussed in recent professional guidelines. METHODS: We systematically reviewed the literature over the past 5 years (2020 to present) to identify studies evaluating noninvasive liver disease assessments (NILDAs) in MASLD. RESULTS: Of the 912 records, 48 met inclusion criteria: 37 through the systematic review and 11 identified by the authors. Of the 15 novel scores, several perform well in steatotic liver disease in validation studies and included routinely available elements. Although several novel scores had good to excellent discrimination, their cost and availability may limit their use in practice. Based on our review, we propose starting with the FIB-4 index, given its availability, low cost, and high negative predictive value. In those with a FIB-4 >1.3, we propose using Agile 3+ or 4 to identify advanced fibrosis or cirrhosis. CONCLUSIONS: NILDAs are effective alternatives to liver biopsy for fibrosis assessment in MASLD and may serve as a tool to identify patients who are candidates for newer therapies.
引用
- Grady JT, Cyrus JW, Sterling RK, et al. Novel Noninvasive Tests for Liver Fibrosis: Moving Beyond Simple Tests in Metabolic Dysfunction-associated Steatotic Liver Disease. Clin Gastroenterol Hepatol. 2025. PMID: 40451522. doi:10.1016/j.cgh.2025.02.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。